KOD

Kodiak Sciences Inc.

$97.04

+$5.72 (6.26%)Oct 28 close

Healthcare Compare Technicals

1M 3M 6M 1Y 2Y

KODSPY

Wall St. Highest PT $145.00 (+49.4%) Wall St. Avg PT $121.67 (+25.4%)

Underwater Drawdown %Max DD -36.2%Current -2.8%

Relative Strength vs SPY+401.4% vs SPYOutperforming

+$9.32 (10.62%)

+$7.12 (7.92%)

+$57.03 (142.54%)

+$53.37 (122.21%)

YTD

+$69.08 (247.07%)

+$77.79 (404.10%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street analyst consensus

Strong Buy

7 analysts · mean score 1.43

1 = Strong Buy · 5 = Sell

Strong Buy571%

Buy114%

Hold114%

Underperform00%

Sell00%

Wall Street consensus · as of Oct 12, 2026

Analyst price targets

Current price$97.04

Average target$121.67

+$24.63 (+25.4%) upsideaverage target vs current price

CurrentAverageMedian

Low$103.00

Median$122.00

High$145.00

12-month Wall Street target range · as of Oct 12, 2026

Recent analyst rating changes · 30

Reiterated

2026-10-12 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-09-28 · LifeSci Capital reiterated Outperform on KOD

Reiterated

2026-09-28 · UBS reiterated Buy on KOD

Reiterated

2026-09-28 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-09-17 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-08-17 · HC Wainwright & Co. reiterated Buy on KOD

All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$5.5B

P/E (next 12 months, estimated)-25.5

52-week range$15.83 – $104.00

Dividend yieldNo dividend

Analyst consensusStrong Buy (6)

Average analyst price target$121.67 (+25%)

What they do

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases.

Healthcare · Biotechnology

Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

For information only · Important disclosures

Grades vs sector

No sector grades for KOD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth

4.0% of the book · ranked 8 of 589

Held Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

SURVYR. Long Book

Not in the current book

Why it's in the New Highs Growth #8 of 589

Qualified on Biotech, +0% from 52-week high, biotech, price-only entry, 12-1 momentum +136%. Ranked 8th of 589 at the 2026-09-30 rebalance.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-28) it ranks 2nd.

Earnings & events

KOD earningsNext report in 14 days

Next report · quarter Sep 2026

Thu Nov 12, 2026Time not confirmed

EPS consensus-$1.01 range -$1.10–-$0.89

Revenue consensus$0 4 analysts

Last 4 quarters · EPS vs estimate

Aug 13, 2026-$1.05est -$0.96−9.8%Below estimates

May 7, 2026-$0.94est -$1.01+7.1%Above estimates

Mar 31, 2026-$1.04est -$1.05+1.2%In line with estimates

Nov 13, 2025-$1.16est -$1.04−11.5%Below estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$0	–
2026-03-31	$0	–
2025-12-31	$0	–
2025-09-30	$0	–
2025-06-30	$0	–

News & catalysts

More news

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

Zacks · Oct 19

Research

New Highs Growth: rebalance of Sep 30, 2026Oct 22, 2026

Rating changes

Reiterated

2026-10-12 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-09-28 · LifeSci Capital reiterated Outperform on KOD

Reiterated

2026-09-28 · UBS reiterated Buy on KOD

Reiterated

2026-09-28 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-09-17 · HC Wainwright & Co. reiterated Buy on KOD

Reiterated

2026-08-17 · HC Wainwright & Co. reiterated Buy on KOD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades

Borgeson John A.